Lilly’s retatrutide beats Ozempic in head-to-head trial
Eli Lilly, a dominant force in the obesity and type 2 diabetes market, has just beaten its biggest rival, with…
Gastrointestinal
-
-
Lilly’s Omvoh leads to 50% clinical remission rate in paediatric UC
Eli Lilly’s Omvoh (mirikizumab-mrkz) has shown a 50% clinical remission rate in paediatric patients with ulcerative colitis (UC). In the…
-
First patient dosed with DISP-10 in Dispatch Bio’s cancer trial
Dispatch Bio has dosed the first participant in a Phase I clinical trial aimed at evaluating the efficacy and safety…
-
Ipsen’s Bylvay fails in Phase III biliary atresia study
Ipsen’s stock has fallen after its rare disease drug Bylvay (odevixibat) failed to show benefit in a Phase III trial…
-
Corxel to advance oral obesity drug to Phase III trials
Corxel Pharmaceuticals’ oral obesity candidate has succeeded in a Phase II trial in the US, teeing it up for a…
-
MSD’s anti-TL1A mAb from $10.8bn acquisition wins in Phase III trial
MSD’s investigational humanised monoclonal antibody targeting tumour necrosis factor-like cytokine 1A (TL1A), which it acquired during a $10.8bn buyout of…
-
DDW: Lilly’s Omvoh shows four-year UC clearance
Eli Lilly’s Omvoh (mirikizumab-mrkz) has shown four-year disease-clearance in patients with moderately to severely active ulcerative colitis (UC). In the…
-
Teva and Sanofi’s TL1A mAb shows durability in UC and CD
Teva Pharmaceuticals and Sanofi’s monoclonal antibody (mAb) has shown durable clinical and endoscopic efficacy in a Phase IIb trial in…
-
First subject enrolled in Bluejay Therapeutics’ trial of Hepatitis D treatment
Bluejay Therapeutics has enrolled the first subject in the randomised AZURE-2 global Phase III clinical trial to assess pan-genotypic, fully…
-
First subject dosed in Resolution’s liver cirrhosis therapy trial
Resolution Therapeutics has dosed the first subject and cleared for safety in its multi-centre Phase I/II EMERALD trial, assessing RTX001,…
